Stockscreener 앱 받기
15.13
1.61%
0.23
Fulgent Genetics Inc 주식(FLGT)의 최신 뉴스
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics - BioSpace
PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics - Business Wire
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2026 Earnings Call Transcript - Insider Monkey
Fulgent Q1 2026 slides: revenue misses amid customer loss, therapy data shines - Investing.com Australia
Fulgent Genetics (FLGT) Trailing US$60 Million Loss Tests Bullish Margin Narratives - Sahm
Fulgent Genetics Inc (FLGT) Q1 2026 Earnings Call Highlights: Na - GuruFocus
Understanding the Setup: (FLGT) and Scalable Risk - Stock Traders Daily
Fulgent Genetics, Inc. Q1 2026 SEC 10-Q Filing: Financial Statements, Company Information, and Risk Disclosure - Minichart
Fulgent Genetics Reports Q1 2026 Results: $71M Revenue, Stock Buyback, Updated Guidance and Progress in Cancer Therapeutics - Minichart
Fulgent Genetics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Is Fulgent Genetics (FLGT) 38.5% Undervalued After Q1 2026? Reve - GuruFocus
Fulgent outlines $350M 2026 revenue outlook following Bako/StrataDx acquisition - MSN
Fulgent (FLGT) Q1 2026 Earnings Transcript - AOL.com
Fulgent Genetics, Inc. (FLGT) reports Q1 loss, beats revenue estimates - MSN
Fulgent Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Fulgent Genetics Posts Q1 Loss, Reaffirms 2026 Outlook - TipRanks
Fulgent Genetics Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Fulgent Genetics disappoints with Q1 2026 results By Investing.com - Investing.com South Africa
Fulgent Reports First Quarter 2026 Financial Results - BioSpace
Earnings call transcript: Fulgent Genetics disappoints with Q1 2026 results - Investing.com
Full Transcript: Fulgent Genetics Q1 2026 Earnings Call - Benzinga
Fulgent Genetics (NASDAQ:FLGT) Shares Dip Premarket After Q1 Earnings Miss Despite Revenue Beat - ChartMill
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Fulgent Genetics (NASDAQ:FLGT) Releases FY 2026 Earnings Guidance - MarketBeat
FLGT: Q1 2026 revenue fell 3% YoY, but growth in drug development and acquisitions support a $350M 2026 outlook - TradingView
FULGENT GENETICS ($FLGT) Releases Q1 2026 Earnings - Quiver Quantitative
[10-Q] Fulgent Genetics, Inc. Quarterly Earnings Report - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) posts Q1 2026 loss, reaffirms $350M revenue outlook - Stock Titan
Fulgent Genetics Inc (FLGT) Q1 2026 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Fulgent Genetics Q1 2026 earnings preview - MSN
Fulgent Genetics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Fulgent Genetics (FLGT) CSO has 1,645 shares withheld for tax obligations - Stock Titan
Fulgent Genetics (FLGT) COO reports tax-withholding share disposition after RSU vesting - Stock Titan
Fulgent Genetics (FLGT) CFO has 2,747 shares withheld for RSU taxes - Stock Titan
Fulgent Reports Second Quarter 2024 Financial Results - 富途牛牛
Fulgent Genetics rises on earnings, revenue beat - MSN
Fulgent Genetics (FLGT) to Release Earnings on Friday - MarketBeat
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting - BioSpace
Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of "Hold" by Analysts - MarketBeat
Fulgent Genetics to present nano-encapsulated anti-tumor drug FID-007 efficacy at ASCO meeting - Traders Union
Head and neck cancer study from Fulgent gets ASCO oral slot - Stock Titan
Fulgent Genetics (FLGT) Stock Pre Market (Momentum Building) 2026-04-18Top Picks - Cổng thông tin điện tử Tỉnh Sơn La
Fulgent Genetics Under Investigation for Securities Law Violations - Intellectia AI
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm - lincolnjournal.com
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics - GlobeNewswire
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026 - BioSpace
Press Release: Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026 - Moomoo
Stock Recap: Whats the analyst consensus on Fulgent Genetics Inc2026 Growth vs Value & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Pullback Watch: Is Fulgent Genetics Inc a momentum stock2026 Levels & Daily Momentum Trading Reports - baoquankhu1.vn
Stop Loss: Can Fulgent Genetics Inc stock outperform in a bear market2026 Biggest Moves & Risk Managed Investment Entry Signals - baoquankhu1.vn
Fulgent Genetics Inc (FLGT) Stock Down 3.9% -- Now Undervalued? GF Score: 64/100 - GuruFocus
Precision Trading with Fulgent Genetics Inc. (FLGT) Risk Zones - Stock Traders Daily
Buyback Watch: What is the long term forecast for Fulgent Genetics Inc stockEarnings Trend Report & Safe Entry Trade Signal Reports - baoquankhu1.vn
Can Fulgent Genetics Inc stock outperform in a bear marketTrade Risk Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Surprises Report: Can Fulgent Genetics Inc stock outperform in a bear market2026 Action & Accurate Buy Signal Alerts - baoquankhu1.vn
0.07%
자본화:
|
볼륨(24시간):